Original language | English |
---|---|
Pages (from-to) | 240-241 |
Number of pages | 2 |
Journal | Psychiatry and clinical neurosciences |
Volume | 75 |
Issue number | 7 |
DOIs | |
Publication status | Published - 07-2021 |
All Science Journal Classification (ASJC) codes
- General Neuroscience
- Neurology
- Clinical Neurology
- Psychiatry and Mental health
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Psychiatry and clinical neurosciences, Vol. 75, No. 7, 07.2021, p. 240-241.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Duration of long-acting injectable antipsychotic treatment and reasons for its discontinuation
T2 - A chart review of patients with schizophrenia
AU - Kishi, Taro
AU - Sakuma, Kenji
AU - Okuya, Makoto
AU - Hatano, Masakazu
AU - Iwata, Nakao
N1 - Funding Information: Drs. Kishi, Sakuma, Okuya, Hatano, and Iwata declare that they have no direct conflicts of interest relevant to this study. Dr. Kishi received speaker's honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Janssen, Otsuka, Meiji, Mochida, MSD, and Tanabe‐Mitsubishi (Yoshitomi), as well as research grants from the Japanese Ministry of Health, Labour, and Welfare, a Grant‐in‐Aid for Scientific Research (C) (19K08082), and Fujita Health University School of Medicine. This work was supported by a Grant‐in‐Aid for Scientific Research (C) (19K08082). This funding source had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results. Dr. Sakuma has received speaker's honoraria from Eisai, Kissei, Meiji, Otsuka, and Torii and has received a Fujita Health University School of Medicine research grant, as well as a Grant‐in‐Aid for Young Scientists (B). Dr. Okuya has received speaker's honoraria from Meiji. Dr. Hatano has received speaker's honoraria from Dainippon Sumitomo and Otsuka. Dr. Iwata received speaker's honoraria from Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Takeda, Meiji, and Pfizer, along with research grants from Daiichi Sankyo, Takeda, Dainippon Sumitomo Eisai, Meiji, Tanabe‐Mitsubishi, and Otsuka. Funding Information: We thank all the participants of this study, which was supported by a Grant‐in‐Aid for Scientific Research (C) (19K08082).
PY - 2021/7
Y1 - 2021/7
UR - http://www.scopus.com/inward/record.url?scp=85107262249&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107262249&partnerID=8YFLogxK
U2 - 10.1111/pcn.13222
DO - 10.1111/pcn.13222
M3 - Letter
C2 - 33934445
AN - SCOPUS:85107262249
SN - 1323-1316
VL - 75
SP - 240
EP - 241
JO - Psychiatry and clinical neurosciences
JF - Psychiatry and clinical neurosciences
IS - 7
ER -